Skip to main content

Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment.

Publication ,  Journal Article
Chapman, BM; Yang, J-C; Gonzalez, JM; Havrilesky, L; Reed, SD; Hwang, ES
Published in: JCO Oncol Pract
November 2021

PURPOSE: Ductal carcinoma in situ (DCIS), a nonobligate precursor of breast cancer, is often aggressively managed with multimodal therapy. However, there is limited research on patients' preferences for trade-offs among treatment-related outcomes such as breast appearance, side effects, and future cancer risk. We sought to investigate whether women consider treatment features aside from cancer risk when making treatment choices for ductal carcinoma in situ and if so, to what degree other features influence these decisions. METHODS: A discrete choice experiment was administered to participants in a comprehensive cancer screening mammography clinic. The experimental design was used to generate constructed health profiles resulting from different management strategies. Health profiles were defined by breast appearance, severity of infection within the first year, chronic pain, hot flashes, and risk of developing or dying from breast cancer within 10 years. RESULTS: One hundred ninety-four women without a personal history of breast cancer completed the choice task. Across 10 choice questions, 29% always selected the health profile with a lower risk of invasive breast cancer (ie, dominated on cancer risk), regardless of the effects of treatment. For nonrisk dominators, breast cancer risk remained the most important factor but was closely followed by chronic pain (24% [95% CI, 20 to 28]) and infection (22% [95% CI, 18 to 25]). Depending on treatment outcomes, the tolerable increase in breast cancer risk was as high as 3.4%. CONCLUSION: Most women were willing to make some trade-offs between invasive cancer risk and treatment-related outcomes. Our findings highlight the importance of shared decision-making weighing risks and benefits between patient and provider management of low-risk disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JCO Oncol Pract

DOI

EISSN

2688-1535

Publication Date

November 2021

Volume

17

Issue

11

Start / End Page

e1639 / e1648

Location

United States

Related Subject Headings

  • Patient Preference
  • Mammography
  • Humans
  • Female
  • Early Detection of Cancer
  • Carcinoma, Intraductal, Noninfiltrating
  • Breast Neoplasms
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chapman, B. M., Yang, J.-C., Gonzalez, J. M., Havrilesky, L., Reed, S. D., & Hwang, E. S. (2021). Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. JCO Oncol Pract, 17(11), e1639–e1648. https://doi.org/10.1200/OP.20.00614
Chapman, Brittany M., Jui-Chen Yang, Juan Marcos Gonzalez, Laura Havrilesky, Shelby D. Reed, and E Shelley Hwang. “Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment.JCO Oncol Pract 17, no. 11 (November 2021): e1639–48. https://doi.org/10.1200/OP.20.00614.
Chapman BM, Yang J-C, Gonzalez JM, Havrilesky L, Reed SD, Hwang ES. Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. JCO Oncol Pract. 2021 Nov;17(11):e1639–48.
Chapman, Brittany M., et al. “Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment.JCO Oncol Pract, vol. 17, no. 11, Nov. 2021, pp. e1639–48. Pubmed, doi:10.1200/OP.20.00614.
Chapman BM, Yang J-C, Gonzalez JM, Havrilesky L, Reed SD, Hwang ES. Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. JCO Oncol Pract. 2021 Nov;17(11):e1639–e1648.

Published In

JCO Oncol Pract

DOI

EISSN

2688-1535

Publication Date

November 2021

Volume

17

Issue

11

Start / End Page

e1639 / e1648

Location

United States

Related Subject Headings

  • Patient Preference
  • Mammography
  • Humans
  • Female
  • Early Detection of Cancer
  • Carcinoma, Intraductal, Noninfiltrating
  • Breast Neoplasms
  • 3211 Oncology and carcinogenesis